Axsome Therapeutics Inc.
Axsome Therapeutics Announces Positive Results for AXS-12 in Narcolepsy Phase 3 Trial
Summary
On November 26, 2024, Axsome Therapeutics, Inc. announced that its AXS-12 product candidate met the primary endpoint in the ENCORE Phase 3 trial for the treatment of narcolepsy. The trial demonstrated a statistically significant improvement in the frequency of cataplexy attacks compared to placebo (p=0.017), along with improvements in cognition, excessive daytime sleepiness, and overall narcolepsy status. AXS-12 was well tolerated with a safety profile consistent with prior trials. The Company plans to move towards an NDA filing for AXS-12.
Profitelligence Alerts
Get alerts for AXSM
Be first to know when Axsome Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Axsome Therapeutics Inc.
Axsome Therapeutics Inc. specializes in the development and commercialization of transformative therapies for central nervous system (CNS) disorders. The company's focus is on addressing unmet medical needs in the fields of depression, migraines, and agitation associated with Alzheimer's disease, among other CNS conditions. Axsome's robust pipeline includes both clinical and preclinical stage compounds, highlighting a commitment to innovation and efficacy. By utilizing novel mechanisms of action, their product candidates aim to offer significant advantages over existing treatments. Axsome Therapeutics plays a crucial role in the pharmaceutical and healthcare sectors, helping reshape treatment paradigms for complex and challenging CNS disorders. Through strategic collaborations and leveraging cutting-edge research methods, the company seeks to provide effective healthcare solutions and improve quality of life for patients globally. Established on a vision to impact lives positively, Axsome continues to advance its clinical programs and regulatory approvals, thereby reinforcing its position in the biotechnology industry.
Official SEC Documents
Advertisement